439 related articles for article (PubMed ID: 27764805)
1. Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy.
Nakamura Y; Kitano S; Takahashi A; Tsutsumida A; Namikawa K; Tanese K; Abe T; Funakoshi T; Yamamoto N; Amagai M; Yamazaki N
Oncotarget; 2016 Nov; 7(47):77404-77415. PubMed ID: 27764805
[TBL] [Abstract][Full Text] [Related]
2. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
Capone M; Giannarelli D; Mallardo D; Madonna G; Festino L; Grimaldi AM; Vanella V; Simeone E; Paone M; Palmieri G; Cavalcanti E; Caracò C; Ascierto PA
J Immunother Cancer; 2018 Jul; 6(1):74. PubMed ID: 30012216
[TBL] [Abstract][Full Text] [Related]
3. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N
J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333
[TBL] [Abstract][Full Text] [Related]
4. Blood Predictive Biomarkers for Nivolumab in Advanced Melanoma.
Chasseuil E; Saint-Jean M; Chasseuil H; Peuvrel L; Quéreux G; Nguyen JM; Gaultier A; Varey E; Khammari A; Dréno B
Acta Derm Venereol; 2018 Apr; 98(4):406-410. PubMed ID: 29327065
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
[TBL] [Abstract][Full Text] [Related]
7. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma.
Indini A; Di Guardo L; Cimminiello C; Prisciandaro M; Randon G; De Braud F; Del Vecchio M
J Cancer Res Clin Oncol; 2019 Feb; 145(2):511-521. PubMed ID: 30539281
[TBL] [Abstract][Full Text] [Related]
8. Prognostic score for patients with advanced melanoma treated with ipilimumab.
Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
[TBL] [Abstract][Full Text] [Related]
9. Association of Inflammatory Markers with Disease Progression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors.
Pan M; Alavi M; Herrinton LJ
Perm J; 2018; 22():17-149. PubMed ID: 29616914
[TBL] [Abstract][Full Text] [Related]
10. Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients.
Khunger M; Patil PD; Khunger A; Li M; Hu B; Rakshit S; Basu A; Pennell N; Stevenson JP; Elson P; Panchabhai TS; Velcheti V
PLoS One; 2018; 13(10):e0197743. PubMed ID: 30359383
[TBL] [Abstract][Full Text] [Related]
11. Correlation between cutaneous adverse events and prognosis in patients with melanoma treated with nivolumab: A single institutional retrospective study.
Nakano E; Takahashi A; Namikawa K; Muto Y; Jinnai S; Kage Y; Mizuta H; Tsutsumida A; Yamazaki N
J Dermatol; 2020 Jun; 47(6):622-628. PubMed ID: 32162349
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
Bagley SJ; Kothari S; Aggarwal C; Bauml JM; Alley EW; Evans TL; Kosteva JA; Ciunci CA; Gabriel PE; Thompson JC; Stonehouse-Lee S; Sherry VE; Gilbert E; Eaby-Sandy B; Mutale F; DiLullo G; Cohen RB; Vachani A; Langer CJ
Lung Cancer; 2017 Apr; 106():1-7. PubMed ID: 28285682
[TBL] [Abstract][Full Text] [Related]
13. The absolute lymphocyte count can predict the overall survival of patients with non-small cell lung cancer on nivolumab: a clinical study.
Karantanos T; Karanika S; Seth B; Gignac G
Clin Transl Oncol; 2019 Feb; 21(2):206-212. PubMed ID: 29948974
[TBL] [Abstract][Full Text] [Related]
14. High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma.
Zaragoza J; Caille A; Beneton N; Bens G; Christiann F; Maillard H; Machet L
Br J Dermatol; 2016 Jan; 174(1):146-51. PubMed ID: 26343230
[TBL] [Abstract][Full Text] [Related]
15. Anti-PD-1 antibodies in metastatic uveal melanoma: a treatment option?
Bender C; Enk A; Gutzmer R; Hassel JC
Cancer Med; 2017 Jul; 6(7):1581-1586. PubMed ID: 28639409
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors of daily blood examination for advanced melanoma patients treated with nivolumab.
Okuhira H; Yamamoto Y; Inaba Y; Kunimoto K; Mikita N; Ikeda T; Kaminaka C; Minami Y; Kanazawa N; Furukawa F; Jinnin M
Biosci Trends; 2018 Sep; 12(4):412-418. PubMed ID: 30158364
[TBL] [Abstract][Full Text] [Related]
17. Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma.
Theurich S; Rothschild SI; Hoffmann M; Fabri M; Sommer A; Garcia-Marquez M; Thelen M; Schill C; Merki R; Schmid T; Koeberle D; Zippelius A; Baues C; Mauch C; Tigges C; Kreuter A; Borggrefe J; von Bergwelt-Baildon M; Schlaak M
Cancer Immunol Res; 2016 Sep; 4(9):744-54. PubMed ID: 27466265
[TBL] [Abstract][Full Text] [Related]
18. A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma.
Weber JS; Sznol M; Sullivan RJ; Blackmon S; Boland G; Kluger HM; Halaban R; Bacchiocchi A; Ascierto PA; Capone M; Oliveira C; Meyer K; Grigorieva J; Asmellash SG; Roder J; Roder H
Cancer Immunol Res; 2018 Jan; 6(1):79-86. PubMed ID: 29208646
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials.
Long GV; Weber JS; Larkin J; Atkinson V; Grob JJ; Schadendorf D; Dummer R; Robert C; Márquez-Rodas I; McNeil C; Schmidt H; Briscoe K; Baurain JF; Hodi FS; Wolchok JD
JAMA Oncol; 2017 Nov; 3(11):1511-1519. PubMed ID: 28662232
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices.
Cowey CL; Liu FX; Black-Shinn J; Stevinson K; Boyd M; Frytak JR; Ebbinghaus SW
J Immunother; 2018; 41(2):86-95. PubMed ID: 29252916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
